These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15501641)

  • 1. Indications for hormone therapy: the post-Women's Health Initiative era.
    Reed SD; Newton KM; Lacroix AZ
    Endocrinol Metab Clin North Am; 2004 Dec; 33(4):691-715. PubMed ID: 15501641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002).
    Barber CA; Margolis K; Luepker RV; Arnett DK
    J Womens Health (Larchmt); 2004 Nov; 13(9):975-85. PubMed ID: 15665654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F; Taylor HS; Karas R; Brinton E; Newman I; Clarkson TB; Mendelsohn M; Lobo RA; Judelson DR; Nachtigall LE; Heward CB; Hecht H; Jaff MR; Harman SM;
    Fertil Steril; 2004 Jun; 81(6):1498-501. PubMed ID: 15193467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. After the Women's Health Initiative: decision making and trust of women taking hormone therapy.
    Schonberg MA; Davis RB; Wee CC
    Womens Health Issues; 2005; 15(4):187-95. PubMed ID: 16051110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a place for postmenopausal hormone therapy use in women with lupus?
    Gompel A; Piette JC
    Panminerva Med; 2008 Sep; 50(3):247-54. PubMed ID: 18927529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?
    Salpeter S
    Climacteric; 2005 Dec; 8(4):307-10. PubMed ID: 16390764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response.
    Hartsfield CL; Connelly MT; Newton KM; Andrade SE; Wei F; Buist DS
    J Natl Cancer Inst Monogr; 2005; (35):113-5. PubMed ID: 16287896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI.
    Hoffmann M; Hammar M; Kjellgren KI; Lindh-Astrand L; Brynhildsen J
    Maturitas; 2005 Sep; 52(1):11-7. PubMed ID: 16023804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women's use of hormone therapy before and after the Women's Health Initiative: a psychosocial model of stability and change.
    Gerend MA; Aiken LS; Erchull MJ; Lapin A
    Prev Med; 2006 Sep; 43(3):158-64. PubMed ID: 16750263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where are we with postmenopausal hormone therapy in 2005?
    Lam PM; Chung TK; Haines C
    Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menopause and stroke and the effects of hormonal therapy.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of hormone therapy in the 50-59 year age group.
    van de Weijer PH
    Maturitas; 2008 May; 60(1):59-64. PubMed ID: 18556157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned from the WHI: HRT requires a cautious and individualized approach.
    Aubuchon M; Santoro N
    Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHI risks: any relevance to menopause management?
    Burger HG
    Maturitas; 2007 May; 57(1):6-10. PubMed ID: 17368974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI.
    Clanget C; Hinke V; Lange S; Fricke R; Botko R; Pfeilschifter J
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):529-33. PubMed ID: 16235155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.